TECNOTREE
Tecnotree, a Finnish global provider of digital transformation solutions for Communication Service Providers (CSPs) and Digital Service Providers (DSPs), announced the go-live of its Digital Service Provisioning System (DSPS), with Zain South Sudan. The successful go-live marked another global footprint for Tecnotree DSPS this year in the African market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220726005561/en/
The solution replaced an existing provisioning system, and allows the operator to leverage the 5G Cloud Native platform to meet their current and future market requirements. The platform will also enable the operator to scale up or down rapidly in response to changes in demand. Tecnotree DSPS is a pre-integrated suite that processes business service logic towards the network, enabling a centralized system for all provisioning-related planning and task management. The product has been designed to provide rapid and highly automated activation and provisioning along with digital services.
Tecnotree DSPS platform provides a foundation for operators and Digital Service Providers to launch new services faster, with greater agility and resource efficiency. The solution makes it easier to plan and design innovative services which can be then launched with zero-touch operations. Centralization of all provisioning processes in DSPS enables high-speed service fulfilment with more assurance and high activation success rate.
“I would like to thank Tecnotree on the successful delivery of the DSPS, we trusted Tecnotree on their digital portfolio and delivery capabilities and they achieved our expectations before time!” said Wilson Lado, CTIO, Zain South Sudan.
Padma Ravichander, CEO of Tecnotree Corporation, said, “Innovation is at the heart of everything we do, which means that we’re constantly striving to provide state-of-the-art technology for our customers. Our DSPS solution is a cloud-ready provisioning platform that allows efficient management of infrastructure and high performance of services, helping our customers optimize business processes with flexible and intelligent digital service provisioning.”
About Tecnotree
Tecnotree is the only full-stack digital business management solution provider for digital service providers, with over 40 years of deep domain knowledge, proven delivery, and transformation capability across the globe. Our open-source technology-based agile products and solutions comprise the full range (order-to-cash) of business process and subscription management for telecom and other digital service providers with a pre-integrated B2B2X partner ecosystem across gaming, health, education, OTT, and more. Tecnotree products, platforms, and partners support emerging ecosystems of over 1 billion subscribers across 70+ countries. Tecnotree is listed on Nasdaq Helsinki (TEM1V). For more information, please visit www.tecnotree.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220726005561/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services5.1.2026 15:00:00 CET | Press release
The acquisition strengthens DIETL’s fine art logistics operations through expanded access to specialized storage, handling and customs services. The Rock-It Company announced today that DIETL has acquired multiple fine art logistics specialists, strengthening its infrastructure and expanding access to specialized services across key U.S. art markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105175923/en/ The Rock-It Company Expands Fine Art Logistics Capabilities of DIETL Through Acquisition of Several Strategic Infrastructure Services The acquired companies include Delaware Freeport, Delaware National Art Company, Techno Export, and Registrar Technologies. Together, these businesses add depth across fine art storage, handling, packing, crating, installation support, customs brokerage, and technology-enabled logistics services, complementing DIETL’s existing operations. Delaware Freeport, a provider of high-security
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release
Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom